SPY756.10−0.49%QQQ682.99−1.07%BTC/USD72,468.66−1.97%DIA524.60+0.03%GLD360.67−1.23%TLT80.79−0.16%

Tango Therapeutics Inc

TNGXNASDAQ

Trade with Public

$25.73

1.435.88%

Last update: Nov 12, 7:09 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Mon Nov 9th, before the market open

Tango Therapeutics (TNGX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Tango Therapeutics (TNGX) stock.

Analyst Consensus — 14 Analysts

14Buy

# Analysts14

Latest Upgrades and Downgrades for Tango Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	JP Morgan	Brian Cheng	PT Raise	Overweight	$46→$47
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$45→$40
—	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$68→$67
—	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$68
—	William Blair	Alethia Young	Initiate	Outperform	—
—	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$66→$68
—	Guggenheim	Michael Schmidt	PT Raise	Buy	$32→$35
—	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$36→$40
—	JP Morgan	Brian Cheng	Initiate	Overweight	$46
—	Canaccord Genuity	John Newman	PT Raise	Buy	$42→$46
—	Jefferies	Maury Raycroft	Upgrade	Hold→Buy	$27→$60
—	Canaccord Genuity	John Newman	Maintained	Buy	$42
—	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$66
—	Canaccord Genuity	John Newman	PT Raise	Buy	$30→$42
—	Leerink Partners	Andrew Berens	PT Raise	Outperform	$55→$69
—	Piper Sandler	Kelsey Goodwin	Downgrade	Overweight→Neutral	$16→$24
—	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$20→$30
—	Jefferies	Maury Raycroft	Downgrade	Buy→Hold	$18→$27
—	Leerink Partners	Andrew Berens	PT Raise	Outperform	$28→$55
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$19→$33

Tango Therapeutics Inc

Tango Therapeutics (TNGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Tango Therapeutics Stock

Tango Therapeutics (TNGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Tango Therapeutics Stock

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

PRO
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

People Also Watch

People Also Watch

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

PRO
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

Tango Therapeutics Inc

Tango Therapeutics (TNGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Tango Therapeutics Stock

Tango Therapeutics (TNGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Tango Therapeutics Stock

Analyst Ratings News

PROJP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

PROWedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

PROHC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67

PROHC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PROWilliam Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PROHC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

People Also Watch

People Also Watch

Analyst Ratings News

PROJP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

PROWedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

PROHC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67

PROHC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PROWilliam Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PROHC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

PRO
JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

PRO
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

PRO
JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47

PRO
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67

PRO
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target

PRO
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68